Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer

Inclusion Criteria: * Patients must have histologically or cytologically confirmed prostate cancer OR a strong suspicion of prostate cancer as evidenced by metastatic disease in a pattern consistent with prostate cancer (such as blastic lesions on a nuclear medicine bone scan or lymphadenopathy on the computed tomography \[CT\] scan) AND a PSA \> 50 ng/mL * Patients must meet either of the definitions for high risk disease as follows: * Definition 1: Must have at least 2 of the following 3 at the time diagnosed metastatic: * visceral metastatic disease * \>=3 bone lesions * Gleason 8-10 OR * Definition 2: \>=4 bone lesions, including \>=1 outside of the vertebral column or pelvis and/or visceral metastatic disease * If a patient has received androgen deprivation therapy (ADT) for neoadjuvant or adjuvant therapy at least 24 months MUST have elapsed since its use to day 1 of restarting ADT for metastatic castration sensitive disease * ADT sensitive disease- no evidence of PSA progression or new metastatic deposits since starting ADT; PSA progression is defined as an increase in PSA greater than 25% above nadir, and \>2 ng/ml increase confirmed by a second value obtained at least 2 weeks apart * Have completed up to 6 cycles of docetaxel since developing metastatic castration sensitive disease with no more than 16 weeks elapsed since day 21 of the final cycle * All races and ethnic groups will be included * Life expectancy of greater than 18 months * Eastern C…